{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Somatostatin+analog&page=2",
    "query": {
      "intervention": "Somatostatin analog",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 33,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Somatostatin+analog&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Somatostatin+analog&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T05:40:32.660Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01677910",
      "title": "TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoid Syndrome"
      ],
      "interventions": [
        {
          "name": "Telotristat etiprate",
          "type": "DRUG"
        },
        {
          "name": "Placebo-matching telotristat etiprate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lexicon Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 135,
      "start_date": "2013-01-08",
      "completion_date": "2016-03-21",
      "has_results": true,
      "last_update_posted_date": "2018-02-27",
      "last_synced_at": "2026-10-05T05:40:32.660Z",
      "location_count": 17,
      "location_summary": "Mobile, Alabama • Palo Alto, California • San Francisco, California + 13 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01677910"
    },
    {
      "nct_id": "NCT03466216",
      "title": "Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "AlphaMedix",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Orano Med LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2018-02-05",
      "completion_date": "2023-04-06",
      "has_results": false,
      "last_update_posted_date": "2025-06-10",
      "last_synced_at": "2026-10-05T05:40:32.660Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03466216"
    },
    {
      "nct_id": "NCT00331188",
      "title": "Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Esophageal Varices",
        "Portal Hypertension",
        "Gastric Varices",
        "Esophageal Bleeding"
      ],
      "interventions": [
        {
          "name": "Sanvar® (vapreotide)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Debiovision",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 70,
      "start_date": "2006-05",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2008-07-08",
      "last_synced_at": "2026-10-05T05:40:32.660Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00331188"
    },
    {
      "nct_id": "NCT01732406",
      "title": "Acromegaly Treatment Quality of Life Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acromegaly"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 126,
      "start_date": "2013-01",
      "completion_date": "2016-12-19",
      "has_results": true,
      "last_update_posted_date": "2019-04-29",
      "last_synced_at": "2026-10-05T05:40:32.660Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01732406"
    },
    {
      "nct_id": "NCT01372618",
      "title": "Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ductal Carcinoma in Situ"
      ],
      "interventions": [
        {
          "name": "SOM 230 / Pasireotide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "21 Years and older · Female only"
      },
      "enrollment_count": 9,
      "start_date": "2011-06",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2017-12-27",
      "last_synced_at": "2026-10-05T05:40:32.660Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01372618"
    },
    {
      "nct_id": "NCT02270567",
      "title": "RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neuroendocrine Tumor",
        "Carcinoid",
        "Neuroendocrine Carcinoma"
      ],
      "interventions": [
        {
          "name": "NETest",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Wren Laboratories LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2015-02",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2025-11-13",
      "last_synced_at": "2026-10-05T05:40:32.660Z",
      "location_count": 1,
      "location_summary": "Branford, Connecticut",
      "locations": [
        {
          "city": "Branford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02270567"
    },
    {
      "nct_id": "NCT02705313",
      "title": "EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "177Lu-DOTA0-Tyr3-Octreotate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advanced Accelerator Applications",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2018-04-09",
      "last_synced_at": "2026-10-05T05:40:32.660Z",
      "location_count": 41,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 33 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02705313"
    },
    {
      "nct_id": "NCT01128192",
      "title": "Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hyperglycemia"
      ],
      "interventions": [
        {
          "name": "pasireotide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Robert R. Henry, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 45,
      "start_date": "2009-08",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2014-12-25",
      "last_synced_at": "2026-10-05T05:40:32.660Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01128192"
    },
    {
      "nct_id": "NCT02795858",
      "title": "A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoid Tumors"
      ],
      "interventions": [
        {
          "name": "Ramucirumab",
          "type": "DRUG"
        },
        {
          "name": "Somatostatin Analog",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2016-06-14",
      "completion_date": "2023-12-31",
      "has_results": true,
      "last_update_posted_date": "2025-02-19",
      "last_synced_at": "2026-10-05T05:40:32.660Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02795858"
    },
    {
      "nct_id": "NCT05249114",
      "title": "Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Lu-177",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Providence Health & Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2022-12-28",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-05T05:40:32.660Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05249114"
    }
  ]
}